Rabia Ozden has joined Akouos as chief development officer. She was most recently the chief medical officer of gene therapy developer Nightstar Therapeutics, which was acquired by Biogen (NASDAQ: BIIB) earlier this year for $800 million. Boston-based Akouos is developing gene therapies to address inherited forms of hearing loss.
UNDERWRITERS AND PARTNERS
